Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 9957 results found since Jan 2013.
The Efficacy of Neoadjuvant Gemcitabine and Cisplatin Chemotherapy for cT3N0M0 Upper Tract Urothelial Carcinoma: The Impact of Tumor Location
CONCLUSION: NAC-GC improves both pathological outcomes and oncological prognosis in patients with cT3N0M0 UTUC. With regard to tumor location, RPT has better pathological outcomes and oncological prognoses than UT.PMID:37634073
Source: Urology Journal - August 27, 2023 Category: Urology & Nephrology Authors: Yuki Kohada Tetsutaro Hayashi Kenshiro Takemoto Syunsuke Miyamoto Takashi Babasaki Kohei Kobatake Hiroyuki Kitano Kenichiro Ikeda Keisuke Goto Keisuke Hieda Yukiko Honda Kazuhiro Sentani Naohide Oue Kazuo Awai Nobuyuki Hinata Source Type: research
Comparison of MRI vs. < sup > 18 < /sup > FFDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives
J Clin Med. 2023 Aug 17;12(16):5355. doi: 10.3390/jcm12165355.ABSTRACTThe purpose of this systematic review was to investigate the diagnostic accuracy of [18F]FDG PET/CT and breast MRI for primary breast cancer (BC) response assessment after neoadjuvant chemotherapy (NAC) and to evaluate future perspectives in this setting. We performed a critical review using three bibliographic databases (i.e., PubMed, Scopus, and Web of Science) for articles published up to the 6 June 2023, starting from 2012. The Quality Assessment of Diagnosis Accuracy Study (QUADAS-2) tool was adopted to evaluate the risk of bias. A total of 76 studi...
Source: Clinical Genitourinary Cancer - August 26, 2023 Category: Cancer & Oncology Authors: Matteo Caracciolo Angelo Castello Luca Urso Francesca Borgia Maria Cristina Marzola Licia Uccelli Corrado Cittanti Mirco Bartolomei Massimo Castellani Egesta Lopci Source Type: research
Screening of Exosome-Derived Proteins and Their Potential as Biomarkers in Diagnostic and Prognostic for Pancreatic Cancer
Int J Mol Sci. 2023 Aug 9;24(16):12604. doi: 10.3390/ijms241612604.ABSTRACTIn the oncological area, pancreatic cancer is one of the most lethal diseases, with 5-year survival rising just 10% in high-development countries. This disease is genetically characterized by KRAS as a driven mutation followed by SMAD4, CDKN2, and TP53-associated mutations. In clinical aspects, pancreatic cancer presents unspecific clinical symptoms with the absence of screening and early plasmatic biomarker, being that CA19-9 is the unique plasmatic biomarker having specificity and sensitivity limitations. We analyzed the plasmatic exosome proteomi...
Source: Cancer Control - August 26, 2023 Category: Cancer & Oncology Authors: Anelis Maria Marin Michel Batista Alexandre Luiz Korte de Azevedo Talita Helen Bombardelli Gomig Rodrigo Soares Caldeira Brant Roger Chammas Miyuki Uno Diogo Dias Ara újo Dalila Luciola Zanette Mateus N óbrega Aoki Source Type: research
Comparison of MRI vs. < sup > 18 < /sup > FFDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives
J Clin Med. 2023 Aug 17;12(16):5355. doi: 10.3390/jcm12165355.ABSTRACTThe purpose of this systematic review was to investigate the diagnostic accuracy of [18F]FDG PET/CT and breast MRI for primary breast cancer (BC) response assessment after neoadjuvant chemotherapy (NAC) and to evaluate future perspectives in this setting. We performed a critical review using three bibliographic databases (i.e., PubMed, Scopus, and Web of Science) for articles published up to the 6 June 2023, starting from 2012. The Quality Assessment of Diagnosis Accuracy Study (QUADAS-2) tool was adopted to evaluate the risk of bias. A total of 76 studi...
Source: Clinical Breast Cancer - August 26, 2023 Category: Cancer & Oncology Authors: Matteo Caracciolo Angelo Castello Luca Urso Francesca Borgia Maria Cristina Marzola Licia Uccelli Corrado Cittanti Mirco Bartolomei Massimo Castellani Egesta Lopci Source Type: research
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
CONCLUSIONS: This triple immunotherapy regimen provided responses in patients with advanced or relapsed HER2-negative breast cancer, at the expense of long-term toxicities.SIGNIFICANCE: Systemic immune checkpoint blockade with a programmed death receptor 1 and a CTL antigen-4 blocking antibody, combined with intralesional oncolytic virotherapy, is a chemotherapy-free combination aimed at inducing an antitumor immune response locally and systemic immunity.PMID:37621406 | PMC:PMC10445661 | DOI:10.1158/2767-9764.CRC-23-0145
Source: Cell Research - August 25, 2023 Category: Cytology Authors: Vina P Nguyen Katie M Campbell Theodore S Nowicki Nila Elumalai Egmidio Medina Ignacio Baselga-Carretero Maggie L DiNome Helena R Chang Denise K Oseguera Antoni Ribas John A Glaspy Source Type: research
Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report
CONCLUSION: This case sheds light on the feasibility and safety of alectinib as a neoadjuvant treatment for stage IIIB NSCLC patients with ALK rearrangement. Its efficacy needs to be validated in prospective clinical trials.PMID:37621597 | PMC:PMC10445061 | DOI:10.12998/wjcc.v11.i22.5322
Source: Clinical Lung Cancer - August 25, 2023 Category: Cancer & Oncology Authors: Lu-Ming Wang Peng Zhao Xu-Qi Sun Feng Yan Qian Guo Source Type: research
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
CONCLUSIONS: Incorporation of atezolizumab into standard therapy for newly diagnosed ovarian cancer does not significantly improve efficacy or impose additional treatment burden for patients.CLINICALTRIALS: gov registration: NCT03038100.PMID:37625235 | DOI:10.1016/j.ygyno.2023.06.018
Source: Gynecologic Oncology - August 25, 2023 Category: Cancer & Oncology Authors: Sandro Pignata Michael Bookman Jalid Sehouli Austin Miller Richard T Penson Cagatay Taskiran Charles Anderson Sakari Hietanen Tashanna Myers Radoslaw Madry Lyndsay Willmott Alain Lortholary Jessica Thomes-Pepin Carol Aghajanian Carolyn McCourt Ashley Stuc Source Type: research
ASO Visual Abstract: Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment
Ann Surg Oncol. 2023 Aug 25. doi: 10.1245/s10434-023-14226-4. Online ahead of print.NO ABSTRACTPMID:37626250 | DOI:10.1245/s10434-023-14226-4
Source: Ann Oncol - August 25, 2023 Category: Cancer & Oncology Authors: Kirithiga Ramalingam Elle Clelland Harriet Rothschild Firdows Mujir Helena Record Mandeep Kaur Rita A Mukhtar Source Type: research
Locoregional Treatment for Early-Stage Breast Cancer: Current Status and Future Perspectives
Curr Oncol. 2023 Aug 10;30(8):7520-7531. doi: 10.3390/curroncol30080545.ABSTRACTBACKGROUND: The locoregional recurrence of breast cancer has been reduced due to the multidisciplinary approach of breast surgery, systemic therapy and radiation. Early detection and better surgical techniques contribute to an improvement in breast cancer outcomes.PURPOSE OF REVIEW: The purpose of this review is to have an overview and summary of the current evidence behind the current approaches to the locoregional treatment of breast cancer and to discuss its future direction.SUMMARY: With improved surgical techniques and the use of a more ef...
Source: Cancer Control - August 25, 2023 Category: Cancer & Oncology Authors: Sayeh Lavasani Erin Healy Kari Kansal Source Type: research
Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial)
This study will assess whether ART is non-inferior to ALND in terms of recurrence and overall survival in patients with positive SLN after NST, including whether it reduces surgery-related adverse effects.METHODS AND ANALYSES: This multicenter, randomized, open-label, phase 3 trial will enroll 1660 patients with breast cancer and positive SLNs following NST in approximately 50 Spanish centers over 3 years. Patients will be stratified by NST regimen and nodal involvement (isolated tumoral cells or micrometastasis versus macrometastasis) and randomly assigned 1:1 to ART without ALND (study arm) or ALND alone (control arm). L...
Source: Cancer Control - August 25, 2023 Category: Cancer & Oncology Authors: Amparo Garcia-Tejedor Carlos Ortega-Exposito Sira Salinas Ana Luzardo-Gonz ález Catalina Falo Evelyn Martinez-P érez H éctor Pérez-Montero M Teresa Soler-Mons ó Maria-Teresa Bajen Ana Benitez Raul Ortega Anna Petit Anna Guma Miriam Campos Maria J Pl Source Type: research
Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report
CONCLUSION: This case sheds light on the feasibility and safety of alectinib as a neoadjuvant treatment for stage IIIB NSCLC patients with ALK rearrangement. Its efficacy needs to be validated in prospective clinical trials.PMID:37621597 | PMC:PMC10445061 | DOI:10.12998/wjcc.v11.i22.5322
Source: Clinical Lung Cancer - August 25, 2023 Category: Cancer & Oncology Authors: Lu-Ming Wang Peng Zhao Xu-Qi Sun Feng Yan Qian Guo Source Type: research
Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study
CONCLUSIONS: Delayed treatment approaching 2 months was observed in 10% of the population. The rising temporal trend in TTT may be attributed to the increasing shift toward neoadjuvant CT/RT in early-stage PDAC and/or the increasing use of tissue biopsy prior to surgery.PMID:37624518 | DOI:10.1245/s10434-023-14221-9
Source: Ann Oncol - August 25, 2023 Category: Cancer & Oncology Authors: Kavin Sugumar Jonathan J Hue Shreya Gupta Mohamedraed Elshami Luke D Rothermel Lee M Ocuin John B Ammori Jeffrey M Hardacre Jordan M Winter Source Type: research
